Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
A-Phase: tirofiban; Z-Phase simvastatin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| A-Phase: tirofiban; Z-Phase simvastatin | DRUG | - |
| Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years | DRUG | - |
| Comparator: A-Phase: low molecular weight heparin, unfractionated heparin | DRUG | - |
| Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours | DRUG | - |
| Duration of Treatment: Z-Phase, 2 years. | DRUG | - |
Inclusion Criteria: * A-Phase: Chest pain at rest for 10 minutes, EKG changes or elevated cardiac blood work * Z-Phase: elevated cholesterol , plus at least one risk factor ( \> 70 years old, diabetes, history of prior heart or blood vessel disease, chest pain with EKG changes, elevation of cardiac...
Tirofiban and simvastatin are used in the treatment of Acute Coronary Syndrome, a condition that includes chest pain or heart attack. The combination was studied in a Phase 3 clinical trial to evaluate the use of two approved drugs in patients who have experienced these events.
Tirofiban and simvastatin are being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The company conducted a Phase 3 clinical trial to study the use of these two drugs in patients with Acute Coronary Syndrome.
Tirofiban and simvastatin are in Phase 3 clinical development for Acute Coronary Syndrome. The Phase 3 trial, which has been completed, enrolled 4,497 patients and was designed to evaluate the use of these two approved drugs in patients who have experienced chest pain or a heart attack.
Tirofiban and simvastatin were studied in a Phase 3 clinical trial registered as NCT00251576, titled 'Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)'. This trial, which has been completed, enrolled 4,497 patients with Acute Coronary Syndrome.